Novo Nordisk, Emcure to launch weight-loss drug under new brand in India (updated)

Emcure Pharmaceuticals

10/11/2025 06:40

Adds details and background from paragraph 2 onwards

Nov 10 (Reuters) - Novo Nordisk NOVOb.CO has partnered with India's Emcure Pharmaceuticals EMCU.NS to exclusively distribute and market its weight-loss drug under a new brand in the country, the companies said on Monday.

Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate  brand of its blockbuster weight-loss treatment Wegovy.

Shares of Emcure Pharma rose following the announcement, trading 6.5% higher at 1,451 rupees.

Novo Nordisk launched Wegovy in India in June, three months after Eli Lilly LLY.N introduced its competing weight-loss product Mounjaro in the world's most populous nation.

Wegovy's 2.4 mg dose is priced at 26,015 rupees for a month's supply in India, while pricing for Poviztra was not disclosed.

"This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India," the Danish company said in an exchange filing.

Last month, Eli Lilly also partnered with Cipla CIPL.NS to sell its weight-loss drug under a separate brand in India.

 (Reporting by Manvi Pant in Bengaluru; Editing by Mrigank Dhaniwala and Sherry Jacob-Phillips)

 ((Manvi.Pant@thomsonreuters.com; +918447554364;))